The APEX1 Knockout Jurkat Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in the Jurkat background, targeting the APEX1 gene. This loss-of-function model serves as a versatile tool for dissecting the roles of the APEX1 protein in DNA repair and redox signaling within T lymphocytes. The polyclonal nature of the knockout pool enables the study of heterogeneous gene-disruption effects across a population, mitigating clonal artifacts. Cells are suitable for functional assays where pooled knockout phenotypes are representative of the mutation spectrum.
Jurkat cells are a widely used human T-cell leukemia line that retains key characteristics of T lymphocytes, including the capacity to activate signaling cascades upon stimulation. Derived from a patient with acute T-cell leukemia, these cells are a principal model for investigating T-cell receptor signaling, apoptosis, and immune activation. The Jurkat line is particularly valued for its manipulability and the extensive body of literature characterizing its signaling networks, making it an ideal host for knockout studies of genes involved in lymphocyte biology.
APEX1 encodes a dual-function enzyme with critical roles in the base excision repair (BER) pathway and in the redox regulation of transcriptional activators. In DNA repair, APEX1 acts as an apurinic/apyrimidinic endonuclease, cleaving the phosphodiester backbone at abasic sites to facilitate subsequent processing by DNA polymerase ?? and XRCC1. In parallel, APEX1 maintains transcription factors such as NF-??B, AP-1, and p53 in a reduced, active state through its redox activity, which is mediated by interactions with thioredoxin. Upstream, APEX1 expression is induced by reactive oxygen species and DNA damage, and it is transcriptionally regulated by p53 and Sp1. Downstream, APEX1 promotes the transcriptional activity of NF-??B and AP-1, linking DNA repair capacity to immune and stress responses.
In Jurkat T cells, APEX1 is integral to the maintenance of genomic integrity and the redox-dependent regulation of transcription factors that drive immune function and leukemogenesis. Disruption of APEX1 in this model enables the dissection of its contribution to DNA damage responses in the context of T-cell signaling, including how oxidative stress influences NF-??B-mediated survival pathways. This knockout model is particularly relevant to leukemia research, as APEX1 overexpression is often associated with chemoresistance; thus, the cells allow the assessment of drug sensitivity in a controlled genetic background.
Researchers can employ this product in a range of assays to investigate DNA repair kinetics, transcription factor activation, and apoptotic responses. Western blotting and RT-qPCR confirm reduced APEX1 expression and downstream target gene modulation, while comet assays measure DNA damage accumulation. Immunofluorescence can assess nuclear translocation of APEX1 or repair proteins, and flow cytometry, along with MTT assays, quantifies apoptosis and drug sensitivity. Reporter gene assays for NF-??B and AP-1 activity provide functional readouts of redox signaling. For further technical specifications, please contact Ascent Research.
